Nonchannel drug targets in atrial fibrillation

Pharmacology and Therapeutics

Volumn 102, Issue 1, 2004, Pages 17-36

  Goette, Andreas ^a   Lendeckel, Uwe ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

A disintegrin and metalloprotease (EC 3.4.24. ); ACE; ADAM; ADAM TS; Angiotensin converting enzyme (CD143, EC 3.4.15.1); Atrial fibrillation; Molecular biology; Pharmacology; Signal transduction; Therapy

Indexed keywords

AMIODARONE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; METALLOPROTEINASE; VON WILLEBRAND FACTOR;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR RISK; CARDIOVERSION; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; GAP JUNCTION; GENE DELETION; GENE INSERTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART ATRIUM THROMBOSIS; HEART MITOCHONDRION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REENTRY ARRHYTHMIA; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOGENESIS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANTIOXIDANTS; ATRIAL FIBRILLATION; HUMANS; METALLOPROTEASES; MYOCARDIUM; OXIDATIVE STRESS; THROMBOSIS;

EID: 1842471341     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.01.001     Document Type: Review

References (203)

1. Abbaszade I., Liu R.-Q., Yang F., Rosenfeld S.A., Ross O.H., Link J.R., Ellis D.M., Tortorella M.D., Pratta M.A., Hollis J.M., Wynn R., Duke J.L., George H.J., Hillman M.C. Jr., Murphy K., Wiswall B.H., Copeland R.A., Decicco C.P., Bruckner R., Nagase H., Itoh Y., Newton R.C., Magolda R.L., Trzaskos J.M., Hollis G.F., Arner E.C., Burn T.C. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem. 274:1999;23443-23450.
2. Aime-Sempe C., Folliguet T., Rucker-Martin C., Krajewska M., Krajewska S., Heimburger M., Aubier M., Mercadier J.J., Reed J.C., Hatem S.N. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol. 34:1999;1577-1586.
3. Allessie M., Ausma J., Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 54:2002;230-246.
4. Andrews T.C., Reimold S.C., Berlin J.A., Antman E.M. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation. 84(Suppl. III):1991;III-236-III-244.
5. Arndt M., Lendeckel U., Röcken C., Nepple K., Zahn C., Huth C., Ansorge S., Klein H.U., Goette A. Altered expression of ADAMs (a disintegrin and metalloproteinase) in fibrillating human atria. Circulation. 105:2002;720-725.
6. Ausma J., Wijffels M., Thone F., Wouters L., Allessie M., Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 96:1997;3157-3163.
7. Ausma J., Dispersyn G.D., Duimel H., Thone F., Ver Donck L., Allessie M.A., Borgers M. Changes in ultrastructural calcium distribution in goat atria during atrial fibrillation. J Mol Cell Cardiol. 32:2000;355-364.
8. Azpitarte J., Alvarez M., Baun O., Garcia R., Moreno E., Martin F., Tercedor L., Fernandez R. Value of single oral loading dose propafenone in converting recent-onset atrial fibrillation: results of a randomized, double-blind, controlled study. Eur Heart J. 18:1997;1649-1654.
9. Azuma H., Ishikawa M., Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol. 88:1986;411-415.
10. Benjamin E.J., Dagostino R.B., Belanger A.J., Wolf P.A., Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 92:1995;835-841.
11. Berglund H., Boukter S., Theodorsson E., Vallin H., Edhag O. Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. Br Heart J. 64:1990;9-13.
12. Berk B.C. Angiotensin II receptors and angiotensin II-stimulated signal transduction. Heart Fail Rev. 3:1998;87-99.
13. Black R.A. Tumor necrosis factor alpha- converting enzyme. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;1315-1317 Academic Press, London, San Diego.
14. Black R.A., White J.M. ADAMs: focus on the protease domain. Curr Opin Cell Biol. 10:1998;654-659.
15. Boixel C., Fontaine V., Rucker-Martin C., Milliez P., Louedec L., Michel J.B., Jacob M.P., Hatem S.N. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 42:2003;336-344.
16. Bosch R.F., Scherer C.R., Rub N., Wohrl S., Steinmeyer K., Haase H., Busch A.E., Seipel L., Kühlkamp V. Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion channel subunits reduces I(Ca,L) and I(to) in rapid atrial pacing in rabbits. J Am Coll Cardiol. 41:2003;858-869.
17. Brand F.N., Abbott R.D., Kannel W.B., Wolf P.A. Characteristics and prognosis of lone atrial fibrillation: 30 years follow-up in the Framingham Study. J Am Med Assoc. 254:1985;3449-3453.
18. Brundel B.J.J.M., Van Gelder I.C., Tuinenburg A.E., Wietses M., Van Veldhuisen D.J., Van Gilst W.H., Crijns H.J., Henning R.H. Endothelin system in human persistent and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 12:2001;737-742.
19. Cai H., Li Z., Goette A., Mera F., Honeycutt C., Feterik K., Wilcox J.N., Dudley S.C. Jr., Harrison D.G., Langberg J.J. Down-regulation of nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 106:2002;2854-2858.
20. CAPRIE Steering Committee A randomized blinded trial of clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 348:1996;1329-1339.
21. Carnes C.A., Chung M.K., Nakayama T., Nakayama H., Baliga R.S., Piao S., Kanderian A., Pavia S., Hamlin R.L., McCarthy P.M., Bauer J.A., Van Wagoner D.R. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 89:2001;e32-e38.
22. Cella G., Bellotto F., Tona F., Sbarai A., Mazzaro G., Motta G., Fareed J. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest. 120:2001;1226-1230.
23. Cerletti C., Evangelista V., Molino M., de Gaetano G. Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Thromb Haemost. 74:1995;218-223.
24. Chang C.M., Wu T.J., Zhou S., Doshi R.N., Lee M.H., Ohara T., Fishbein M.C., Karagueuzian H.S., Chen P.S., Chen L.S. Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. Circulation. 103:2001;22-25.
25. Chen Y.J., Chen S.A., Chen Y.C., Yeh H.I., Chan P., Chang M.S., Lin C.I. Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillation. Circulation. 104:2001;2849-2854.
26. Chen Y.J., Chen Y.C., Chan P., Lin C.I., Chen S.A. Angiotensin II increases the arrhythmogenic activity of pulmonary vein myocytes. PACE. 26(II):2003;632. (abstract).
27. Chun S.H., Sager P.T., Stevenson W.G., Nademanee K., Middlekauff H.R., Singh B.N. Long-term efficacy of amiodarone for maintenance of normal sinus rhythm in patients with refractory atrial fibrillation and flutter. Am J Cardiol. 76:1995;47-50.
28. Chung N.A., Belgore F., Li-Saw-Hee F.L., Conway D.S., Blann A.D., Lip G.Y. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 33:2002;2187-2191.
29. Cleutjens J.P., Kandala J.C., Guarda E., Guntaka R.V., Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 27:1995;1281-1292.
30. Coker M.L., Doscher M.A., Thomas C.V., Galis Z.S., Spinale F.G. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol. 277:1999;H777-H787.
31. Coker M.L., Jolly J.R., Joffs C., Etoh T., Holder J.R., Bond B.R., Spinale F.G. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol. 281:2003;H543-H551.
32. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 106:2002;1962-1967.
33. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 107:2003;3141-3145.
34. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the β2-adrenergic receptor to different G proteins by kinase A. Nature. 390:1997;88-91.
35. Davis M.E., Cai H., Drummond G.R., Harrison D.G. Shear stress regulates endothelial nitric oxide synthase expression through c-Src by divergent signaling pathways. Circ Res. 89:2001;1073-1080.
36. De Mello W.C., Crespo M.J. Correlation between changes in morphology, electrical properties and angiotensin converting enzyme activity in the failing heart. Eur J Pharmacol. 378:1999;187-194.
37. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 87:2000;e1-e9.
38. Doshi R.N., Wu T.J., Yashima M., Kim Y.H., Ong J.J., Cao J.M., Hwang C., Yashar P., Fishbein M.C., Karagueuzian H.S., Chen P.S. Relation between ligament of Marshall and adrenergic atrial tachyarrhythmia. Circulation. 100:1999;876-883.
39. EAFT Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 342:1993;1255-1262.
40. Ebihara Y., Haist J.V., Karmazyn M. Modulation of endothelin-1 effects on rat hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP. J Mol Cell Cardiol. 28:1996;265-277.
41. Elg M., Gustafsson D., Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res. 94:1999;187-197.
42. Eriksson B.I., Bergqvist D., Kälebo P., Dahl O.E., Lindbratt S., Bylock A., Frison L., Eriksson U.G., Welin L., Gustafsson D. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 360:2002;1441-1447.
43. Eriksson H., Wåhlander K., Gustafsson D., Welin L.T., Frison L., Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 1:2003;41-47.
44. Eriksson U.G., Bredberg U., Gislén K., Johansson L.C., Frison L., Ahnoff M., Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 59:2003;35-43.
45. Eriksson U.G., Bredberg U., Hoffmann K.-J., Thuresson A., Gabrielsson M., Ericsson H., Ahnoff M., Gislen K., Fager G., Gustafsson D. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 31:2003;294-305.
46. Eriksson-Lepkowska M., Thuresson A., Johansson S., Larsson M., Frison L., Bylock A., Eriksson U.G. The effect of the oral direct thrombin inhibitor ximelagatran on the pharmacokinetics of P450-metabolized drugs, in healthy male volunteers. Blood. 98:2001;89b. (abstract).
47. Everett T.H. IV, Li H., Mangrum J.M., McRury I.D., Mitchell M.A., Redick J.A., Haines D.E. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation. 102:2000;1454-1460.
48. Fatkin D., Kuchar D.L., Thorburn C.W., Feneley M.P. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for atrial stunning as a mechanism of thrombembolic complications. J Am Coll Cardiol. 23:1994;307-316.
49. Francis G.S. ACE inhibition in cardiovascular diseases. N Engl J Med. 342:2000;201-202.
50. Francis C.W., Davidson B.L., Berkowitz S.D., Lotke P.A., Ginsberg J.S., Lieberman J.R., Webster A.K., Whipple J.P., Peters G.R., Colwell C.W. Jr. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med. 137:2002;648-655.
51. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 100:1997;350-356.
52. Fritz G. Human APE/Ref-1 protein. Int J Biochem Cell Biol. 32:2000;925-929.
53. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 96:1997;1180-1184.
54. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 98:2001;1626-1662.
55. Fukuchi M., Watanabe J., Kumagai K., Katori Y., Baba S., Fukuda K., Yagi T., Iguchi A., Yokoyama H., Miura M., Kagaya Y., Sato S., Tabayashi K., Shirato K. Increased von Willebrand Factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 37:2001;1436-1442.
56. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects. Am J Cardiol. 74:1994;236-241.
57. Furlan M., Robles R., Lamie B. Partial purification and characterization of a protease from human plasma cleaving von-Willebrand-factor of fragments produced by in vivo proteolysis. Blood. 87:1996;4223-4234.
58. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., Krause M., Scharrer I., Aumann V., Mittler U., Solenthaler M., Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 339:1998;1578-1584.
59. ATP in the heart - what happens, and what does not happen. Basic Res Cardiol. 95:2000;275-279.
60. Gaspo R., Sun H., Fareh S., Levi M., Yue L., Allen B.G., Hebert T.E., Nattel S. Dihydropyridine and beta adrenergic receptor binding in dogs with tachycardia-induced atrial fibrillation. Cardiovasc Res. 42:1999;434-442.
61. Gensini F., Padeletti L., Fatini C., Sticchi E., Gensini G.F., Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol. 26:2003;295-298.
62. Goette A., Honeycutt C., Langberg J.J. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 94:1996;2968-2974.
63. Goette A., Arndt M., Röcken C., Staack T., Geller J.C., Huth C., Ansorge S., Klein H.U., Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 101:2000;2678-2681.
64. Goette A., Staack T., Arndt M., Röcken C., Geller C., Huth C., Ansorge S., Klein H.U., Lendeckel U. Increased expression of extracellular-signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 35:2000;1669-1677.
65. Goette A., Ittenson A., Hoffmanns P., Reek S., Hartung W., Klein H.U., Ansorge S., Geller J.C. Increased expression of P-selectin during chronic atrial fibrillation. Pacing Clin Electrophysiol. 23(II):2000;1872-1875.
66. Goette A., Geller J.C., Weber M., Welte T., Lutze G., Klein H.U. Effect of heavy exercise on platelet aggregability and endothelial function in patients with chronic atrial fibrillation. Eur Heart J. 21:2000;7. (Suppl.).
67. Goette A., Juenemann G., Peters B., Klein H.U., Roessner A., Huth C., Röcken C. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc Res. 54:2002;390-396.
68. Goette A., Röcken C., Nepple K., Lendeckel U. Proteases and arrhythmias. Hooper N.M., Lendeckel U. Proteases in Biology and Disease: Vol. 1. Proteases in Tissue Remodeling of Lung and Heart. 2003;191-218 Kluwer Academic/Plenum, New York.
69. Graham R.M., Perez D.M., Hwa J., Piascik M.T. α1-Adrenergic receptor subtypes: molecular structure, function, and signaling. Circ Res. 78:1996;737-749.
70. 2+-channel, β-adrenoreceptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res Cardiol. 96:2001;82-90.
71. Gustafsson D., Nyström J., Carlsson S., Bredberg U., Eriksson U., Gyzander E., Elg M., Antonsson T., Hoffmann K., Ungell A., Sorensen H., Nagard S., Abrahamsson A., Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 101:2001;171-181.
72. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G., Garrigue S., Le Mouroux A., Le Metayer P., Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 339:1998;659-666.
73. Hart R.G., Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke. 32:2001;803-808.
74. Heath E.I., Grochow L.B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 59:2000;1043-1055.
75. Heit J.A., Colwell C.W., Francis C.W., Ginsberg J.S., Berkowitz S.D., Whipple J., Peters G. AstraZeneca Arthroplasty Study Group Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med. 161:2001;2215-2221.
76. Henry W.L., Morganroth J., Pearlman A.S., Clark C.E., Redwood D.R., Itscoitz S.B., Epstein S.E. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation. 53:1976;273-279.
77. Herbert J.M., Tissinier A., Defreyn G., Maffrand J.P. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 13:1993;1171-1179.
78. Hoit B.D. Matrix metalloproteinases and atrial structural remodeling (editorial comment). J Am Coll Cardiol. 42:2003;345-347.
79. Hoit B.D., Takeishi Y., Cox M.J., Gabel M., Kirkpatrick D., Walsh R.A., Tyagi S.C. Remodeling of the left atrium in pacing-induced atrial cardiomyopathy. Mol Cell Biochem. 238:2002;145-150.
80. Hooper N.M., Karran E.H., Turner A.J. Membrane protein secretases. Biochem J. 321:1997;265-279.
81. Horowitz L.N., Spielman S.R., Greenspan A.M., Mintz G.S., Morganroth J., Brown R., Brady P.M., Kay H.R. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 6:1985;1402-1407.
82. + exchange inhibitor, on the ion transport of myocardial mitochondria. Mol Cell Biochem. 219:2001;83-90.
83. Hughes A.D. Molecular and cellular mechanisms of action of angiotensin II (AT1) receptors in vascular smooth muscle. J Hum Hypertens. 12:1998;275-281.
84. Hunt M.J., Aru G.M., Hayden M.R., Moore C.K., Hoit B.D., Tyagi S.C. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol. 283:2002;L239-L245.
85. Hurskainen T.L., Hirohata S., Seldin M.F., Aptes S.S. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J Biol Chem. 274:1999;25555-25563.
86. Iga K., Izumi C., Inoko M., Kitaguchi S., Himura Y., Gen H., Konishi T. Increased thrombin-antithrombin III complex during an episode of paroxysmal atrial fibrillation. Int J Cardiol. 66:1998;153-156.
87. Insel P.A. Adrenergic receptors: evolving concepts and clinical applications. N Engl J Med. 334:1996;580-585.
88. Jayachandran J.V., Sih H.J., Winkle W., Zipes D.P., Hutchins G.D., Olgin J.E. Atrial fibrillation by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation. 14:2000;1185-1191.
89. Jayachandran J.V., Zipes D.P., Weksler J., Olgin J.E. Role of the Na(+)/H(+) exchanger in short-term atrial electrophysiological remodeling. Circulation. 101:2000;1861-1866.
90. Jones S.P., Teshima Y., Akao M., Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 93:2003;697-699.
91. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 108:2003;1395-1403.
92. Kageyama S., Yamamoto H., Nagano M., Ariska H., Kayahara T., Yoshimoto R. Antithrombotic effects and bleeding risk of AjvW-2, a monoclonal antibody against human von-Willebrand factor. Br J Pharmacol. 122:1997;165-171.
93. Kalman J.M., Munawar M., Howes L.G., Louis W.J., Buxton B.F., Gutteridge G., Tonkin A.M. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg. 60:1995;1709-1715.
94. Kamath S., Chin B.S., Blann A.D., Lip G.Y. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis. 13:2002;627-636.
95. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 306:1982;1018-1022.
96. Kawara T., Derksen R., de Groot J.R., Coronel R., Tasseron S., Linnenbank A.C., Hauer R.N., Kirkels H., Janse M.J., de Bakker J.M. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation. 104:2001;3069-3075.
97. Kim Y.M., Zhang Y.H., Guzik T.J., Kattach H., Pillai R., Channon K.M., Casadei B. A myocardial nox2 containing NADPH oxidase contributes to oxidative stress in human atrial fibrillation. Circulation. 108:2003;IV-45. (abstract, Suppl.).
98. Kokame K., Matsumoto M., Soejima K., Yagi H., Ishizashi H., Funato M., Tamai H., Konno M., Kamide K., Kawano Y., Miyata T., Fujimura Y. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 99:2002;11902-11907.
99. Kühlkamp V., Schirdewan A., Stangl K., Homberg M., Ploch M., Beck O.A. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 36:2000;139-146.
100. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 41:2003;2197-2204.
101. Kuno K., Kanada K., Nakashima E., Fujiki F., Ichimura F., Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinases- disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem. 272:1997;556-562.
102. Lee R.T. Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc Med. 11:2001;202-205.
103. Lee S.H., Chen S.A., Tai C.T., Chiang C.E., Wen Z.C., Chen Y.J., Yu W.C., Huang J.L., Fong A.N., Cheng J.J., Chang M.S. Comparison of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol. 79:1997;905-908.
104. Lefkowitz R.J., Pitcher J., Krueger K., Daaka Y. Mechanisms of β-adrenergic receptor desensitization and resensitization. Adv Pharmacol. 42:1997;416-420.
105. Lendeckel U., Arndt M., Wrenger S., Nepple K., Huth C., Ansorge S., Klein H.U., Goette A. Expression and activity of ectopeptidases in fibrillating human atria. J Mol Cell Cardiol. 33:2001;1273-1281.
106. Levitt N.C., Eskens F.A., O'Byrne K.J., Propper D.J., Denis L.J., Owen S.J., Choi L., Foekens J.A., Wilner S., Wood J.M., Nakajima M., Talbot D.C., Steward W.P., Harris A.L., Verweij J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res. 7:2001;1912-1922.
107. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., Yang A.Y., Siemieniak D.R., Stark K.R., Gruppo R., Sarode R., Shurin S.B., Chandrasekaran V., Stabler S.P., Sabio H., Bouhassira E.E., Upshaw J.D. Jr., Ginsburg D., Tsai H.M. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413:2001;488-494.
108. Li Y.-Y., Feldman A.M. Matrix metalloproteinases and myocardial remodeling in heart failure. Hooper N.M., Lendeckel U. Proteases in Biology and Disease: Vol. 1. Proteases in Tissue Remodeling of Lung and Heart. 2003;157-189 Kluwer Academic/Plenum, New York.
109. Li D., Fareh S., Leung T.K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 100:1999;87-95.
110. Li Y.-Y., McTiernan C.F., Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 46:2000;214-224.
111. Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 104:2001;2608-2614.
112. Lin P.H., Lee S.H., Su C.P., Wie Y.H. Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation. Free Radic Biol Med. 35:2003;1310-1318.
113. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., Crawford J., Black S., Libby P., Mitchell P.G., Lee R.T. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 105:2002;753-758.
114. Lindstedt K.A., Wang Y., Shiota N., Saarinen J., Hyytiainen M., Kokkonen J.O., Keski-Oja J., Kovanen P.T. Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J. 15:2001;1377-1388.
115. Lip G.Y.H., Lip P., Zarifis J., Watson R.D., Bareford D., Lowe G.D., Beevers D.G. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low dose warfarin and aspirin. Circulation. 94:1996;425-431.
116. Lip G.Y., Lowe G.D., Rumley A., Dunn F.G. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J. 131:1996;724-730.
117. Li-Saw-Hee F.L., Blann A.D., Gurney D., Lip G.Y. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 22:2001;1741-1747.
118. Luttrell L.M., Ferguson S.S., Daaka Y., Miller W.E., Maudsley S., Della Rocca G.J., Lin F., Kawakatsu H., Owada K., Luttrell D.K., Caron M.G., Lefkowitz R.J. Beta-arrestin-dependent formation of beta2 adrenergic receptor-src protein kinase complex. Science. 283:1999;655-661.
119. Macrez N., Morel J.L., Kalkbrenner F., Viard P., Schultz G., Mironneau J. A betagamma dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca2+ channels in rat portal vein myocytes. J Biol Chem. 272:1997;23180-23185.
120. Madrid A.H., Bueno M.G., Rebollo J.M., Marin I., Pena G., Bernal E., Rodriguez A., Cano L., Cano J.M., Cabeza P., Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 106:2002;331-336.
121. Marin F., Roldan V., Climent V., Garcia A., Marco P., Lip G.Y. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke. 34:2003;1181-1186.
122. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 83:1998;1182-1191.
123. Matsumoto T., Wada A., Tsutamoto T., Ohnishi M., Isono T., Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 107:2003;2555-2558.
124. McEuen A.R., Sharma B., Walls A.F. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim Biophys Acta. 1267:1995;115-121.
125. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., Bauer J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 104:2001;174-180.
126. Minamino T., Kitakaze M., Sato H., Asanuma H., Funaya H., Koretsune Y., Hori M. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol. 17:1997;3191-3195.
127. Minamino T., Kitakaze M., Sanada S., Asanuama H., Kurotobi T., Koretsune Y., Fukunami M., Kuzuya T., Hoki N., Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation. Role of nitric oxide. Circulation. 98:1998;1721-1727.
128. Moake J.L., Rudy C.K., Troll J.H., Weinstein M.J., Colannino N.M., Azocar J., Seder R.H., Hong S.L., Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 307:1982;1432-1435.
129. Mondillo S., Sabatini L., Agricola E., Ammaturo T., Guerrini F., Barbati R., Pastore M., Fineschi D., Nami R. Correlation with left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol. 75:2000;227-232.
130. Morillo C.A., Klein G.J., Jones D.L., Guiraudon C.M. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 91:1995;1588-1595.
131. Mujumdar V.S., Tyagi S.C. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens. 17:1999;261-270.
132. Murohara T., Parkinson S.J., Waldman S.A., Lefer A.M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets: role of protein kinase C. Arterioscler Thromb Vasc Biol. 15:1995;2068-2075.
133. Musgrave I.F., Foucart S., Majewski H. Evidence that angiotensin II enhances noradrenaline release from sympathetic nerves in mouse atria by activating protein kinase C. J Auton Pharmacol. 11:1991;211-220.
134. Nagatomo Y., Carabello B.A., Coker M.L., McDermott P.J., Nemoto S., Hamawaki M., Spinale F.G. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol. 278:2000;H151-H161.
135. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 101:2000;2612-2617.
136. Namba T., Koike H., Murakami K., Aoki M., Makino H., Hashiya N., Ogihara T., Kaneda Y., Kohno M., Morishita R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation. 108:2003;2250-2257.
137. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 415:2002;219-226.
138. Nitta T., Imura H., Bessho R., Hosaka H., Yamauchi S., Tanaka S. Wavelength and conduction inhomogeneity in each atrium in patients with isolated mitral valve disease and atrial fibrillation. J Cardiovasc Electrophysiol. 10:1999;521-528.
139. Primakoff P., Myles D.G. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 16:2000;83-87.
140. Radomski M.W., Palmer R.M., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 92:1987;181-187.
141. Rakhit A., Maguire C.T., Wakimoto H., Gehrmann J., Li G.K., Kelly R.A., Michel T., Berul C.I. In vivo electrophysiologic studies in endothelial nitric oxide synthase-deficient mice. J Cardiovasc Electrophysiol. 12:2001;1302-1303.
142. Röcken C., Peters B., Juenemann G., Saeger W., Klein H.U., Huth C., Roessner A., Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 106:2002;2091-2097.
143. Rogg H., de Gasparo M., Graedel E., Stulz P., Burkart F., Eberhard M., Erne P. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J. 17:1996;1112-1120.
144. ATP channels: role in cardioprotection. Cardiovasc Res. 55:2002;429-437.
145. Patella V., Marino I., Arbustini E., Lamparter-Schummert B., Verga L., Adt M., Marone G. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 97:1998;971-978.
146. Pedersen O.D., Bagger H., Køber L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 100:1999;376-380.
147. Perlstein I., Burton D.Y., DeFelice S., Frame L., Coulter D., Levy R.J. Gene therapy for atrial arrhythmias: local overexpression of a clarithromycin sensitive ion channel mutation. [abstract] Circulation. 108:2003;IV-148. Suppl.
148. Peters N.S., Schilling R.J., Kanagaratnam P., Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 359:2002;593-603.
149. Petersen P., Grind M., Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 41:2003;1445-1451.
150. Peterson J.T., Hallak H., Johnson L., Li H., O'Brien P.M., Sliskovic D.R., Bocan T.M., Coker M.L., Etoh T., Spinale F.G. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 103:2001;2303-2309.
151. Pitcher J.A., Freedman N.J., Lefkowitz R.J. G protein-coupled receptor kinases. Annu Rev Biochem. 67:1998;653-692.
152. Plaimauer B., Zimmermann K., Volkel D., Antoine G., Kerschbaumer R., Jenab P., Furlan M., Gerritsen H., Lammle B., Schwarz H.P., Scheiflinger F. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 100:2002;3626-3632.
153. Plewan A., Lehmann G., Ndrepepa G., Schreieck J., Alt E.U., Schomig A., Schmitt C. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs. bisoprolol. Eur Heart J. 22:2001;1504-1510.
154. Pyle W.G., Smith T.D., Hofmann P.A. Cardioprotection with κ-opioid receptor stimulation is associated with a slowing of cross-bridge cycling. Am J Physiol Heart Circ Physiol. 279:2000;H1941-H1948.
155. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., McClure K.F., Mitchell P.G., Libby P., Lee R.T. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99:1999;3063-3070.
156. Schotten U., Ausma J., Stellbrink C., Sabatschus I., Vogel M., Frechen D., Schoendube F., Hanrath P., Allessie M.A. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation. 103:2001;691-698.
157. Schotten U., Duytschaever M., Ausma J., Eijsbouts S., Neuberger H.R., Allessie M. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation. 107:2003;1433-1439.
158. Seccia T.M., Bettini E., Vulpis V., Quartaroli M., Trist D.G., Gaviraghi G., Pirrelli A. Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Pressure. 8:1999;57-64.
159. Seeland U., Böhm M. Cardiac remodeling in pressure overload hypertrophy. Hooper N.M., Lendeckel U. Proteases in Biology and Disease: Vol. 1. Proteases in Tissue Remodeling of Lung and Heart. 2003;127-137 Kluwer Academic/Plenum, New York.
160. Shapiro W., Klein G. Alterations in cardiac function immediately following electrical cardioversion of atrial fibrillation to normal sinus rhythm. Circulation. 38:1968;1074-1084.
161. Shinagawa K., Mitamura H., Ogawa S., Nattel S. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res. 54:2002;438-446.
162. Shirani J., Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol. 9:2000;95-101.
163. Shiroshita-Takeshita A., Shi Y.F., Beatch G., Ezrin A., Tardif J.C., Nattel S. Differential efficacy with antioxidant properties on atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Circulation. 108:2003;IV-148. (abstract, Suppl.).
164. Spach M.S., Heidlage J.F., Dolber P.C., Barr R.C. Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol. 34:2001;69-76. (Suppl.).
165. Sperry J.L., Deming C.B., Bian C., Walinsky P.L., Kass D.A., Kolodgie F.D., Virmani R., Kim A.Y., Rade J.J. Wall tension is a potent negative regulator of in vivo thrombomodulin expression. Circ Res. 92:2003;41-47.
166. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., Goldberg A.T., Zellner J.L., Crumbley A.J. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 102:2000;1944-1949.
167. Struthers A.D. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 2:1996;47-54.
168. Sugden P.H., Clerk A. Regulation of the ERK subgroup of MAP kinase cascade through G protein-coupled receptors. Cell Signal. 9:1997;337-351.
169. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 101:2000;2981-2988.
170. Swiatkowska M., Cierniewska-Cieslak A., Pawlowska Z., Cierniewski C.S. Dual regulatory effects of nitric oxide on plasminogen activator inhibitor type 1 expression in endothelial cells. Eur J Biochem. 267:2000;1001-1007.
171. Takahashi T., Lee R.T. Ischemia/myocardial infarction. The role of matrix metalloproteinases. Hooper N.M., Lendeckel U. Proteases in Biology and Disease: Vol. 1. Proteases in Tissue Remodeling of Lung and Heart. 2003;139-155 Kluwer Academic/Plenum, New York.
172. Tang B.L., Hong W. ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett. 444:1999;223-225.
173. Taylor M.L., Ilton M.K., Misso N.L.A., Watkins D.N., Hung J., Thompson P.J. The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils. Br J Clin Pharmacol. 46:1998;139-145.
174. Teshima Y., Akao M., Jones S.P., Marban E. Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway. Circulation. 108:2003;2275-2281.
175. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 339:1998;1585-1594.
176. Tsutsumi Y., Matsubara H., Ohkubo N., Mori Y., Nozawa Y., Murasawa S., Kijima K., Maruyama K., Masaki H., Moriguchi Y., Shibasaki Y., Kamihata H., Inada M., Iwasaka T. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 83:1998;1035-1046.
177. Turitto V.T., Hall C.L. Mechanical factors affecting hemostasis and thrombosis. Thromb Res. 92:1998;S25-S31.
178. Turpaev K.T. Reactive oxygen species and regulation of gene expression. Biochemistry. 67:2002;281-292.
179. Uehara Y., Urata H., Ideishi M., Arakawa K., Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 55:2002;870-876.
180. Ueng K.C., Tsai T.P., Yu W.C., Tsai C.F., Wu D.J., Lin C.S., Chen C.Y., Chen S.A. Can enalapril facilitate sinus rhythm maintenance after external cardioversion of long-standing atrial fibrillation? PACE. 26(II):2003;154. (abstract).
181. Unverferth D.V., Fertel R.H., Unverferth B.J., Leier C.V. Atrial fibrillation in mitral stenosis: histologic, hemodynamic and metabolic factors. Int J Cardiol. 5:1984;143-154.
182. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res. 66:1990;883-890.
183. Ushio-Fukai M., Alexander R.W., Akers M., Griendling K.K. P38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem. 273:1998;15022-15029.
184. Van Den Berg M.P., Crijns H.J.G.M., Van Veldhuisen D.J. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1:1995;355-364.
185. Van der Velden H.M., Ausma J., Rook M.B., Hellemons A.J., van Veen T.A., Allessie M.A., Jongsma H.J. Gap junction remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res. 101:2000;476-486.
186. van Eickels M., Grohe C., Lobbert K., Stimpel M., Vetter H. Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn Schmiedebergs Arch Pharmacol. 359:1999;394-399.
187. Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., Said S.A., Darmanata J.I., Timmermans A.J., Tijssen J.G., Crijns H.J. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 347:2002;1834-1840.
188. Vermes E., Tardif J.C., Bourassa M.G., Racine N., Levesque S., White M., Guerra P.G., Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Circulation. 107:2003;2926-2931.
189. Ward C.M., Andrews R.K., Smith A.I., Berndt M.C. Mocarhagin, a novel cobra venom metalloprotease, cleaves the platelet von-Willebrand-factor receptor glycoprotein Ibα Biochemistry. 35:1996;4929-4938.
190. Wijffels M.C.E.F., Kirchhof C.J.H.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 92:1995;1954-1968.
191. Wolfsberg T.G., White J.M. ADAMs in fertilization and development. Dev Biol. 180:1996;389-401.
192. Wolfsberg T.G., White J.M. ADAM metalloproteinases. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;1310-1313 Academic Press, London, San Diego.
193. Wolfsberg T.G., Primakoff P., Myles D.G., White J.M. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol. 131:1995;275-278.
194. Workman A.J., Kane K.A., Russell J.A., Norrie J., Rankin A.C. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res. 58:2003;518-525.
195. Wu D., Vanhoorelbeke K., Cauwenberghs N. Inhibition of the von-Willebrand-factor-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 99:2002;3623-3628.
196. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., Corley S.D. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 347:2002;1825-1833.
197. Yamamoto S., Higuchi Y., Yoshiyama K., Shimizu E., Kataoka M., Hijiya N., Matsuura K. ADAM family proteins in the immune system. Immunol Today. 20:1999;278-284.
198. 2+ overload in ischemic/reperfused rat hearts. J Cardiovasc Pharmacol. 39:2002;569-575.
199. Yamashita T., Hayami N., Ajiki K., Oikawa N., Sezaki K., Inoue M., Omata M., Murakawa Y. Is ACE gene polymorphism associated with lone atrial fibrillation? Jpn Heart J. 38:1997;637-641.
200. Yamashita T., Sekiguchi A., Iwasaki Y.K., Sagara K., Hatano S., Iinuma H., Aizawa T., Fu L.T. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation. 108:2003;2450-2452.
201. Yamazaki T., Komuro I., Kudoh S., Zou Y., Shiojima I., Mizuno T., Takano H., Hiroi Y., Ueki K., Tobe K., Kadowaki T., Nagai R., Yazati Y. Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin Invest. 96:1995;438-446.
202. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 276:2001;41059-41063.
203. Zou Y., Komuro I., Yamazaki T., Kudoh S., Aikawa R., Zhu W., Shiojima I., Hiroi Y., Tobe K., Kadowaki T., Yazaki Y. Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts. Circ Res. 82:1998;337-345.